These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7973460)

  • 1. The effects of thymopentin on the development of SLE-like syndrome in the MRL/lpr-lpr mouse.
    Nicoletti F; Zaccone P; Magro G; Barcellini W; Cavallaro V; Belli G; Cocuzza C; di Marco R; Meroni PL
    Scand J Immunol; 1994 Nov; 40(5):549-56. PubMed ID: 7973460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice.
    Nicoletti F; Di Marco R; Zaccone P; Xiang M; Magro G; Grasso S; Morrone S; Santoni A; Shoenfeld Y; Garotta G; Meroni P
    Eur J Immunol; 2000 Feb; 30(2):438-47. PubMed ID: 10671199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
    Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of (S)-armepavine from Nelumbo nucifera on autoimmune disease of MRL/MpJ-lpr/lpr mice.
    Liu CP; Tsai WJ; Shen CC; Lin YL; Liao JF; Chen CF; Kuo YC
    Eur J Pharmacol; 2006 Feb; 531(1-3):270-9. PubMed ID: 16413531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
    J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.
    Cai Z; Wong CK; Dong J; Chu M; Jiao D; Kam NW; Lam CW; Tam LS
    Clin Exp Immunol; 2015 Aug; 181(2):253-66. PubMed ID: 25845911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
    Kikawada E; Lenda DM; Kelley VR
    J Immunol; 2003 Apr; 170(7):3915-25. PubMed ID: 12646661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of autoimmune MRL/Mp-lpr/lpr mice with cholera toxin.
    Fan JL; Himeno K; Tsuru S; Nomoto K
    Clin Exp Immunol; 1987 Oct; 70(1):94-101. PubMed ID: 3500817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of human lupus-like phenotypes in MRL/lpr mice by overexpression of interleukin 27 receptor alpha (WSX-1).
    Sugiyama N; Nakashima H; Yoshimura T; Sadanaga A; Shimizu S; Masutani K; Igawa T; Akahoshi M; Miyake K; Takeda A; Yoshimura A; Hamano S; Yoshida H
    Ann Rheum Dis; 2008 Oct; 67(10):1461-7. PubMed ID: 18094002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell-derived IFN-γ downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus.
    Düster M; Becker M; Gnirck AC; Wunderlich M; Panzer U; Turner JE
    Eur J Immunol; 2018 Aug; 48(8):1364-1375. PubMed ID: 29671873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
    J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of CD40 siRNA on inflammatory response of MRL/Lpr mice].
    Wang ZH; Zhang W; Zhang YQ; Pang CY; Wang YF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):771-776. PubMed ID: 27752154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
    Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
    Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
    Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.
    Mishra N; Reilly CM; Brown DR; Ruiz P; Gilkeson GS
    J Clin Invest; 2003 Feb; 111(4):539-52. PubMed ID: 12588892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of administration of apoptotic blebs on disease development in lupus mice.
    Fransen JH; Berden JH; Koeter CM; Adema GJ; Van Der Vlag J; Hilbrands LB
    Autoimmunity; 2012 Jun; 45(4):290-7. PubMed ID: 22390780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-10 regulates murine lupus.
    Yin Z; Bahtiyar G; Zhang N; Liu L; Zhu P; Robert ME; McNiff J; Madaio MP; Craft J
    J Immunol; 2002 Aug; 169(4):2148-55. PubMed ID: 12165544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
    J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse.
    Nicoletti F; Meroni P; Di Marco R; Barcellini W; Borghi MO; Gariglio M; Mattina A; Grasso S; Landolfo S
    Immunopharmacology; 1992; 24(1):11-6. PubMed ID: 1452442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I IFN protects against murine lupus.
    Hron JD; Peng SL
    J Immunol; 2004 Aug; 173(3):2134-42. PubMed ID: 15265950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.